论文部分内容阅读
20例初治急性髓性白血病(AML)经重组人GM-CSF(rh-GM-CSF)和标准诱导化疗联合治疗,并以相同的39例单纯化疗历史性回顾作为对照组以探讨rh-GM-CSF对白血病造血细胞的调节作用。rh-GM-CSF250μg/m~2·d连续静滴,从化疗前48～24小时至外周血中性杆状核、分叶核粒细胞达500/mm~3以上时改为125μg/m~2每天二次皮下注射,持续3天。治疗前白细胞数(WBC)大于30000/mm~3时,rh-GM-CSF改在化疗引起WBC下降后
Twenty cases of newly diagnosed acute myeloid leukemia (AML) were treated with recombinant human GM-CSF (rh-GM-CSF) and standard induction chemotherapy. The same 39 cases of chemotherapy alone were used as control group to investigate the effects of rh-GM Regulatory Effect of CSF on Leukemic Hematopoietic Cells. rh-GM-CSF250μg / m ~ 2 · d continuous intravenous infusion, from 48 to 24 hours before chemotherapy to the peripheral blood of the primate nucleus, lobular neutrophils up to 500 / mm ~ 3 above 125μg / m ~ 2 subcutaneous injection twice daily for 3 days. Treatment of white blood cell count (WBC) is greater than 30000 / mm ~ 3, rh-GM-CSF change caused by chemotherapy decreased WBC